Physiologic jaundice is common during the newborn transitional period and is seen in approximately two-thirds of all well term infants. The condition results from the abrupt cessation of bilirubin (BR) clearance by the placenta and a transient deficiency in hepatic BR uptake, intracellular transport, and glucuronyltransferase conjugation. Neonates with isoimmune hemolytic disease (e.g., Rhesus and ABO incompatibility) or other hemolytic conditions (e.g., glucose-6-phosphate dehydrogenase deficiency) present with significantly elevated BR production rates and as a consequence, increased serum BR levels. Thus, the degree of hyperbilirubinemia is determined by the balance between BR production and elimination. 1, 2 Currently, the two most widely used treatments for excessive neonatal hyperbilirubinemia are phototherapy and exchange transfusion. These therapies only remove BR that has already been produced and accumulated in vascular and extravascular tissues. However, the suppression of BR formation is a more rational treatment strategy. For example, by preventing the increase in BR production associated with hemolytic disease, it should be possible to prevent the concomitant severe hyperbilirubinemia and the risk for kernicterus. 3 An effective preventive strategy is based firstly on the early, rapid, and accurate identification of those infants at risk for severe hyperbilirubinemia. The traditional diagnostic method is to measure serum total BR (STB) levels. However, this method is invasive and requires several sequential samplings, resulting in blood loss and increased risks for infection. In addition, measurements of STB levels are subject to significant analytical method errors. 4 Because carbon monoxide (CO) is produced in equimolar amounts with BR, its quantitation can be used to index heme degradation as well as BR production ( Figure 1) . Thus, the rate of total body BR production can be estimated by measuring the CO concentration in blood (COHb) or through noninvasive measurements of the total body (pulmonary) CO excretion rate (VeCO) or end-tidal breath CO concentrations (ETCO). To truly reflect only endogenous CO production, these parameters should be corrected for inhaled CO (COHbc and ETCOc). 5, 6 Finally, noninvasive estimations of STB concentrations are also being used as tools toward the identification of neonates at risk through the use of transcutaneous bilirubinometers, such as the Jaundice Meter (Minolta/Airshields, Japan) and the BiliCheck System (SpectRx, Norcross, GA). 7 The second aspect of the strategy is the administration of a safe and effective chemopreventive agent. Because heme oxygenase (HO) is the rate-limiting enzyme in the formation of BR from heme, 8 its inhibition results in decreased CO and BR production rates. Natural and synthetic structural analogs of heme (FePP, iron porphyrin), or (metallo)porphyrins (Mps), have been found to be effective in vitro and in vivo competitive inhibitors of HO (Figure 1 ). Pioneering work by Maines in 1981 9 led to the proposal that these compounds can be used as chemopreventive agents. To date, the identified effective inhibitors include the metal-free (Mf), zinc (Zn 2 + ), tin (Sn 4 + ), chromium (Cr 2 + ), manganese (Mn 2 + ), copper (Cu 2 + ), nickel (Ni 2 + ), and magnesium (Mg 2 + ) porphyrins, with ring modifications to yield deutero-(DP), proto-(PP), meso-(MP), and bis glycol (BG) derivatives (Figure 2 ). Not surprisingly, the diagnostic tools described previously can also be used to monitor the efficacy, and even some side effects, of these potential drugs.
The physiologic impact of modulating HO activity, CO formation, and BR production in the neonatal period, however, is not yet fully appreciated. Recent studies that identify HO as a stress protein, CO as a potential neurotransmitter and vasodilator, and BR as an antioxidant, also suggest significant physiologic roles of HO beyond the turnover of heme and the maintenance of iron stores. 10 Furthermore, the administration of certain Mps can upregulate HO and lead to an increase, rather than a decrease, in HO activity. Finally, Mps are not silver bullets, which affect only HO activity. With our collaborators, we have shown that nitric oxide synthase (NOS) and soluble guanylyl cyclase (sGC) activity as well as the process of lipid peroxidation can be inhibited in vitro by Mps. 11, 12 The attenuation of these enzymes and processes may crucially affect cellular responsiveness to the changing environment during the transitional period. Therefore, it is important to study the effects that Mps may exert on the ontogeny of HO and related aspects of 
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developmental heme biology and physiology to identify the safest and most efficacious compounds. Although HO is fairly ubiquitous throughout the body, its activity varies among tissues. On the basis of heme availability, organ capacity, and specific HO activity, the potential for heme degradation is greatest in the spleen and liver. Considering organ mass and the availability of dietary and biliary heme, the intestine may also be an important, but often overlooked, site of heme degradation. 13 To date, studies have identified the presence of two primary and well-described isoforms of HO, the inducible HO-1 and the constitutive or ''housekeeping'' HO-2. The ratio of these isoforms is not consistent across tissues. For example, HO-1 is the predominant isoform in adult rat spleen, whereas both isoforms are present in adult rat liver (1:1 ratio). In the adult and neonatal rat brain, the predominant isoform is the constitutive HO-2. Certain biochemical characteristics of the intestinal epithelium are consistent with the 14 SnPP, the first and most widely studied synthetic Mp, has been found to inhibit HO activity in vitro and suppress neonatal hyperbilirubinemia in rodents, nonhuman primates, and human neonates in vivo. Its meso derivative (SnMP), however, has become favored because it has comparable efficacy in adult rodents at 10-fold lower doses. 15 In an early clinical trial, SnMP reduced serum BR by 41% in preterm newborns. 16 In a more recent study, a single intramuscular dose of 6.0 mol/kg BW totally eliminated the need for phototherapy during the postnatal period. 17 However, even SnMP may not be the most optimal jaundice preventive compound. For example, it must be administered intramuscularly, is a photosensitizer, contains a foreign metal, induces HO-1 gene in the liver, and inhibits other enzyme systems (such as NOS, sGC). ZnPP, the naturally occurring Mp, is also an effective, but less potent, in vitro and in vivo inhibitor of tissue HO activity and found to suppress hyperbilirubinemia in neonatal rodents and nonhuman primates. 18 In addition, we have shown that ZnMP has comparable in vivo efficacy as ZnPP at 10-fold lower doses. Chernick and coworkers 19 and our laboratory 20 have shown that ZnBG is an extremely potent inhibitor of adult rat and human HO activity. In neonatal rodents, CrMP has also been reported to be a very effective inhibitor of HO activity. 21 Other Mps, such as the copper complexes also demonstrate efficacy, but these compounds require further testing. 22 As with the administration of any drug, there can be adverse metabolic consequences of Mp therapy. Some Mps are photosensitizers, which produce singlet oxygen, and as a result, lead to membrane damage and possibly cell death. Therefore, this particular side effect may limit their clinical use, particularly in infants being treated simultaneously with phototherapy or exposed to light. To identify compounds with maximum HO inhibitory potency and minimum photoreactivity, we evaluated HO inhibition in post mitochondrial supernatants of liver tissue from adult Wistar rats through CO production and photoreactivity by measuring the photogeneration of CO from model organic compounds. Prior screening of the zinc porphyrins led to our early application of these compounds for HO inhibition in vivo with no apparent phototoxicity. When we tested the following Mps: SnPP, SnMP, ZnPP, ZnMP, MnPP, MnMP, CrPP, CrMP, NiPP, and MgPP, we found that ZnPP is 
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Alternative Mps essentially light insensitive, whereas SnPP and SnMP are photosensitizers. We therefore concluded that besides the Zn compounds, the Mn and Cr analogs merit further consideration as potential antihyperbilirubinemic drugs because of their relative high HO inhibitory potency and low photoreactivity. 23 We further studied the in vitro characteristics of six additional Mps: CrDP, FeBG, ZnDP, MfBG, SnBG, and SnDP and used ZnPP as a nonphotosensitizing reference. Photoreactivity, rat liver HO inhibition, and Mp metabolism were studied as described above. Only FeBG, which is structurally and chemically similar to heme (FePP), was metabolized. ZnDP, MfBG, SnBG, and SnDP were found to be significant photosensitizers with different potencies. Of the nonphotoreactive compounds studied in this series, CrDP and ZnDP appear to be the most promising inhibitors. 22 To identify additional nonphotosensitizing inhibitors, we studied other BG derivatives. We found that ZnBG is the most potent inhibitor identified to date, but the compound is also photoreactive. In contrast, MnBG and CrBG were not photoreactive. All three compounds significantly inhibited HO activity of liver, kidney, and brain homogenates in vitro. For spleen homogenates, the I 50 (M) for each compound were: MnBG (150), CrBG (1.5), and ZnBG (0.1). 24 Thus, MnBG was the least potent HO inhibitor. CrBG appeared to be as potent as ZnPP, but less than SnMP. Therefore, besides ZnPP, CrBG may be a potential useful compound.
To date, no systematic studies have evaluated whether the two isoforms of HO are differentially sensitive to inhibition by specific Mps. If this were so, it would allow separate targeting for inhibition of inducible HO-1 or noninducible HO-2 (basal level) processes. Thus, we studied the effects of 12 Mps on total HO activity in rat brain and spleen tissues. The greatest difference in I 50 (M) between spleen (HO-1) and brain (HO-2) occurred with SnPP (0.65 vs. 0.08, eight-fold) showing the most specificity, followed by SnDP (5.5 vs. 0.93, six-fold), then SnMP (0.08 vs. 0.02, four-fold). Noteworthy differences were also found with ZnBG (0.30 vs. 0.07, four-fold). With the other Mps studied, no significant differences were found. Interestingly, for both tissues and thus HO isoforms, inhibitor potency followed the same order: SnMP (0.08 vs. 0.02), CrMP (0.08 vs. 0.04), and ZnBG (0.30 vs. 0.07). Therefore, we concluded that a wide spectrum of HO activity inhibitory potential exists between Mps and that some Mps have a greater affinity for the HO-1 than the HO-2 isoform. 25 In addition to these differential effects, the route of administration can influence Mp bioavailability and efficacy. Oral delivery of a liquid drug is the most suitable route of administration to neonates. However, information on the effects of oral administration and subsequent intestinal absorption of Mps is incomplete, fragmented, and inconclusive. When 40 mol ZnBG/ kg BW was administered by catheter into the small intestine of suckling rats, we found plasma levels of 5 M ZnBG by 30 minutes and 9.4 M in the liver after 30 minutes. Overall, 4.6% of the administered ZnBG dose was found in the plasma and tissues. Oral administration of 25 mol SnPP/kg BW resulted in inhibition of intestinal HO, whereas, no effect was observed in other tissues such as spleen, liver, or kidney. When these latter tissues were analyzed for Sn 4 + , essentially no evidence of intestinal absorption of the Mp could be demonstrated. Oral administration of 25 mol CrMP/kg BW resulted in inhibition of intestinal and hepatic HO activity, but neither ZnMP nor MnMP administration affected HO activity of either tissue. 26 SnMP produced a dose-and time-dependent inhibition of intestinal HO in another study. This inhibition was independent of the iron status of the animal and was apparent whether heme was administered orally or parenterally. When the effects of CrMP, CrPP, and CrBG on hepatic and splenic HO activity were determined following oral delivery, it was found that CrMP significantly reduced HO activity in both the liver and the spleen suggesting that CrMP is an effective candidate for oral administration. 27 Previous work confirmed that heme is excreted in the bile of adult and suckling rats following parenteral administration of Mps. Because of intestinal heme degradation and the enterohepatic circulation of BR that occurs in newborns, BR can reaccumulate in the circulation through these processes. Therefore, inhibition of intestinal HO in neonates is paramount to the success of parenteral and enteral administration of these drugs.
Because neonatal hyperbilirubinemia is a transitional condition, the ideal chemopreventive agent should have a relatively short duration of action and limited residence time. Little, however, is known about the distribution, duration of action, and metabolism of administered Mps. Cobalt protoporphyrin, besides the iron porphyrins, appears to be the only Mp that is a substrate for HO and is therefore metabolized like heme. Only 50% of administered SnPP was recovered in a 7-day pharmacologic study using adult rats. In neonatal rats, SnPP may be retained in tissues for up to 3 weeks. 28 The duration of action of 40 mol ZnPP/kg BW in neonatal rats was found to be less than 1 week and only a modest, and transient, increase in hepatic HO-1 protein levels was observed 24 hours after intraperitoneal administration of this inhibitor. 29 In neonatal rhesus monkeys treated with ZnPP, the ZnPP content of erythrocytes increased for several weeks after dosing. 30 Furthermore, differences in the plasma half-life of SnPP in human adults and neonates suggest that developmental changes affect the pharmacokinetics of these compounds. 31 Evidence is accumulating that CO may not just be an inert by-product of heme degradation, but that it may also be a physiologically active gas, with properties like NO, and affect the activity of sGC. 10 For instance, in the rat brain, the distribution of HO closely parallels that of sGC. Therefore, studies discerning a physiologic role for HO and its products requires inhibitors that will selectively inhibit HO activity without affecting the activity of either NOS, sGC, or other (enzyme) systems. Appleton et al. 11 tested a series of Mps for these particular characteristics. HO activity in rat brain microsomes and NOS activity in rat brain cytosol were measured in the presence of 0.15 to 50 M ZnPP, ZnBG, CrMP, SnPP, and zinc N-methylprotoporphyrin. CrMP and ZnBG were found to be the most selective by inhibiting HO activity 89% and 80%, respectively, without affecting NOS activity. Rat lung cytosol was then incubated with 0.15 to 15 M CrMP or ZnBG and assayed for sGC activity. ZnBG did not affect basal sGC activity, but did potentiate S-nitroso-Nacetylpenicillamine (SNAP)-induced sGC activity. CrMP did not affect either basal or SNAP-induced activity. Of the five Mps studied, CrMP was found to be a selective inhibitor of HO activity at 5 M and may be a valuable tool in elucidating the physiologic role of HO in rat brain.
Through the use of the HO assay, we have the ability to accurately determine the potential for CO production in tissues. However, it may also be instructive to know the amount of CO accumulated in tissues as a result of perturbations, including the administration of Mps. Therefore, we developed a sensitive method for determining tissue CO concentrations. 32 We found that tissues, harvested from untreated adult male Wistar rats and Balb/C mice, had the following CO concentrations (mean±SD, pmol CO/mg FW), respectively: blood (47±10, 45±5); spleen (11±3, 6±1); heart (6±3, 6±1); kidney (5±2, 7±2); muscle (4±4, 10±1); liver (4±1, 5±1); brain (2±1, 2±0); lung (2±1, 3±1); intestine (2±1, 4±2); testes (1±1, 2±1). Between the rat and mouse tissues only the spleen and muscle were found to have significantly different (p<0.05) CO concentrations. We concluded that, whereas blood has the highest CO concentrations as expected, tissues such as spleen, heart, kidney, muscle, and liver, which are rich in hemoglobin and other hemoproteins, also contain substantial amounts of CO. Brain, lung, intestine, and testes contain the lowest concentration of CO. Further studies are in progress to delineate the effects of inhaled CO, hemolysis, the metabolism of methylene chloride (to CO), etc. on tissue CO concentrations.
We have recently developed a hemolytic mouse (Balb/C) model for studying the in vivo efficacy of Mps with measurements of VeCO using a flow-through chamber system. 33 The basal VeCO rates were established before mice were injected through the tail vein with 30 mol heme arginate/kg. At various times during the VeCO measurement period, animals were sacrificed for determination of hepatic and splenic HO activity. The VeCO of untreated animals (58±10 l CO/hr/kg BW) did not change during the 6-hour monitoring period. However, the VeCO of heme-treated animals started to increase 15±5 minutes after injection, and after 78±15 minutes, reached a peak VeCO of 202±27 l CO/hr/kg BW. The VeCO returned to baseline 6 hours after administration. During the study period, splenic HO activity (mean±SD, pmol CO/hr/mg FW) did not change significantly from baseline (555±82). In contrast, the hepatic HO activity (basal=141±29) began to increase approximately 1.5 hours after heme injection, reached a plateau at 2.5±1 hours of 719±75 pmol CO/hr/mg FW, then slowly diminished from 6 hours to 12 days when 138% of baseline HO activity, or 19% of peak HO activity, remained. We have concluded that the mouse is an attractive hemolytic model for the study of HO inhibitors, because it allows for easy intravenous administration of heme and Mps and displays a relatively rapid and reproducible VeCO profile in comparison to the rat model. Furthermore, we have improved the sensitivity of the HO activity assay so that the activity in organs weighing as little as 50 mg can be easily determined. This study demonstrated for the first time that hepatic HO activity upregulation in the mouse occurs quickly and shortly (1.5 hours) after heme injection, and remained at a high level for days, whereas the injected heme was metabolized rather quickly. In contrast, splenic HO activity was not increased because this organ apparently is maximally active.
We are continuing our studies with the following Mps on the basis of what we consider as the most desirable balance between the presently known positive and negative characteristics:
(1) ZnPP. A naturally occurring (result of iron deficiency, lead intoxication) Mp of moderate potency (I 50 for spleen and brain: 7.4 and 5.3 M, respectively), least likely to be toxic. It is not a serious photosensitizer nor stable under acid (gastric) conditions (therefore, not orally absorbable). It upregulates HO-1 (two-fold) in cell culture and is not degraded by HO. Administration by any type of invasive procedure (injection) has attendant infection risks and potential problems with excessive local inhibitor concentrations and slow absorption into the circulation.
(2) ZnBG. A synthetic derivative of ZnPP of very high potency (I 50 spleen and brain: 0.3 and 0.07 M, respectively). It is orally absorbable, a photosensitizer like SnMP and SnPP, does not increase HO-1 transcription in cell culture, and is not degraded by HO. This is perhaps the most promising compound because of its great potency, which may reduce its photoreactivity to insignificance and its biocompatible metal.
(3) CrMP. A synthetic Mp of high potency (I 50 spleen and brain: 0.08 and 0.02 M, respectively). It is orally absorbable, does not cross the blood-brain barrier, is photochemically inactive, does not upregulate HO-1 in cell culture, and is not degraded by HO. This compound could be administered in a low dose that only affects HO-1, but not NOS or sGC activity. We believe that this compound is also very promising.
(4) SnMP. A synthetic Mp of high potency (I 50 spleen and brain: 0.08 and 0.02 M, respectively). It is not orally absorbable, shown to be effective for the suppression of plasma BR levels, does not appear to cross the blood-brain barrier, possesses photoreactive properties like SnPP and ZnBG, has been shown to moderately upregulate HO-1 (two-fold) in cell culture, and is not degraded by HO. A desirable HO inhibitor and the only compound currently approved as an investigational drug.
SUMMARY
Despite intense investigation of many different Mps, no particular chemical structural feature of Mps has been identified that allows us to predict which compound would be the most effective. This may be not too surprising when one considers that what makes a desirable drug for the suppression of neonatal jaundice depends on a balance of not only chemical but also on several physiologic features. A promising compound should have a low I 50 (such as that found 
